CytRx (CYTR) Prices 8M Offering; Sees Gross Proceeds of $20M

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, announced today the pricing of its previously announced underwritten public offering. CytRx is offering 8,000,000 shares of common stock at a public offering price of $2.50 per share for gross proceeds of $20 million, prior to deducting the underwriting discount and estimated offering expenses payable by CytRx.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
• UDynamics files for Nasdaq IPO of 5.6 million shares at $5-$7 per share
• Noodles & Company (NDLS) files $100M mixed shelf